Streetbeat News

Analyst Ratings

BROS

D

LYB

SMCI

Jim Cramer recommends Dominion Energy as a buy for its potential in providing cheap power. He also expresses approval of Dutch Bros' slowed expansion. Super Micro Computer faces a compliance issue with Nasdaq, and Cramer is not recommending LyondellBasell despite its recent earnings beat.

Portfolio Pulse from Avi Kapoor

September 23, 2024 | 12:38 pm

ORIC

Cantor Fitzgerald analyst Prakhar Agrawal has reiterated an Overweight rating on ORIC Pharmaceuticals, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:37 pm

RVPH

EF Hutton has initiated coverage on Reviva Pharmaceuticals with a Buy rating and set a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:36 pm

DYN

Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Dyne Therapeutics, maintaining a price target of $53.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:36 pm

GPCR

Cantor Fitzgerald has reiterated its Overweight rating on Structure Therapeutics (NASDAQ:GPCR) and maintained a price target of $65.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:35 pm

TSLA

Cantor Fitzgerald analyst Andres Sheppard has reiterated a Neutral rating on Tesla (NASDAQ:TSLA) and maintained a price target of $245.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:33 pm

IMNN

EF Hutton has initiated coverage on Imunon (NASDAQ:IMNN) with a Buy rating and set a price target of $29, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:32 pm

NAMS

Piper Sandler has reiterated its Overweight rating on NewAmsterdam Pharma (NASDAQ:NAMS) and maintained a price target of $37.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:30 pm

MSFT

DA Davidson has downgraded Microsoft from Buy to Neutral, setting a price target of $475.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:30 pm

CORZ

Canaccord Genuity has initiated coverage on Core Scientific (NASDAQ:CORZ) with a Buy rating and set a price target of $16.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:26 pm